NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, was featured in an article on Psychiatrist.com, the home of the Journal of Clinical Psychiatry. The article, titled 'How NRx Could Upend the Fight Against Depression and Suicide,' highlights the company's pipeline products NRX-100 and NRX-101.
NRX-101 is a twice-daily oral combination of D-cycloserine and lurasidone designed to treat suicidal treatment-resistant bipolar depression. Research indicates it may be more effective than lurasidone alone in reducing akathisia and suicidality. NRX-100, a proprietary preservative-free formulation of IV ketamine, is being studied as a treatment for acute suicidal crises in depression.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), un'azienda biofarmaceutica in fase clinica, è stata protagonista di un articolo su Psychiatrist.com, la casa del Journal of Clinical Psychiatry. L'articolo, intitolato 'Come NRx potrebbe rivoluzionare la lotta contro la depressione e il suicidio,' evidenzia i prodotti in fase di sviluppo dell'azienda, NRX-100 e NRX-101.
NRX-101 è una combinazione orale da assumere due volte al giorno di D-cicloserina e lurasidone, progettata per trattare la depressione bipolare resistente ai trattamenti e con pensieri suicidari. Le ricerche suggeriscono che potrebbe essere più efficace del solo lurasidone nel ridurre l'acatisia e i pensieri suicidari. NRX-100, una formulazione proprietaria senza conservanti di ketamina IV, è in fase di studio come trattamento per le crisi suicidarie acute nella depressione.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), una empresa biofarmacéutica en fase clínica, fue destacada en un artículo en Psychiatrist.com, el hogar del Journal of Clinical Psychiatry. El artículo, titulado 'Cómo NRx podría revolucionar la lucha contra la depresión y el suicidio,' resalta los productos en desarrollo de la empresa, NRX-100 y NRX-101.
NRX-101 es una combinación oral que se toma dos veces al día de D-cicloserina y lurasidona, diseñada para tratar la depresión bipolar resistente al tratamiento con pensamientos suicidas. La investigación indica que podría ser más efectiva que la lurasidona sola en la reducción de la acatisia y los pensamientos suicidas. NRX-100, una formulación propietaria sin conservantes de ketamina IV, se está estudiando como tratamiento para crisis suicidas agudas en la depresión.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)는 임상 단계의 바이오 제약 회사로, Psychiatrist.com 기사에 소개되었습니다. 이 기사는 Journal of Clinical Psychiatry의 본거지입니다. 기사 제목은 'NRx가 우울증 및 자살과의 싸움을 어떻게 전복할 수 있는가'로, 회사의 파이프라인 제품인 NRX-100 및 NRX-101을 강조합니다.
NRX-101은 D-사이클로세린과 루라시돈의 하루 두 번 복용하는 경구 조합으로, 치료에 저항성이 있는 양극성 우울증에서의 자살을 치료하도록 설계되었습니다. 연구에 따르면 이는 루라시돈만 사용할 때보다 불안 증상과 자살 사고를 줄이는 데 더 효과적일 수 있다고 합니다. NRX-100은 IV 케타민의 독점 보존제가 없는 제형으로, 우울증의 급성 자살 위기 치료법으로 연구되고 있습니다.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), une entreprise biopharmaceutique en phase clinique, a été mise en avant dans un article sur Psychiatrist.com, le site du Journal of Clinical Psychiatry. L'article, intitulé 'Comment NRx pourrait bouleverser la lutte contre la dépression et le suicide,' met en lumière les produits en développement de l'entreprise, NRX-100 et NRX-101.
NRX-101 est une combinaison orale à prendre deux fois par jour de D-cyclosérine et de lurasidone, conçue pour traiter la dépression bipolaire résistante au traitement avec tendances suicidaires. La recherche indique qu'elle pourrait être plus efficace que le lurasidone seul pour réduire l'akathisie et les pensées suicidaires. NRX-100, une formulation propriétaire sans conservateurs de kétamine IV, est à l'étude comme traitement des crises suicidaires aiguës dans la dépression.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ein biopharmazeutisches Unternehmen in der klinischen Phase, wurde in einem Artikel auf Psychiatrist.com, dem Sitz des Journal of Clinical Psychiatry, hervorgehoben. Der Artikel mit dem Titel 'Wie NRx den Kampf gegen Depression und Suizid revolutionieren könnte,' hebt die Pipeline-Produkte des Unternehmens, NRX-100 und NRX-101, hervor.
NRX-101 ist eine oral zweimal täglich einzunehmende Kombination aus D-Cycloserin und Lurasidon, die zur Behandlung von suizidalen behandlungsresistenten bipolaren Depressionen entwickelt wurde. Studien ergeben, dass es möglicherweise effektiver ist als Lurasidon allein, um Akathisie und Suizidalität zu reduzieren. NRX-100, eine proprietäre, konservierungsmittelfreie Formulierung von IV-Ketamin, wird als Behandlung für akute suizidale Krisen bei Depression untersucht.
- Featured in a prominent psychiatric publication, potentially increasing visibility and credibility
- Developing two promising treatments for bipolar depression and suicidal ideation
- NRX-101 showed higher efficacy than existing treatment in reducing akathisia and suicidality
- None.
- "How NRx Could Upend the Fight Against Depression and Suicide"
The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:
- "Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
- "NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
- "NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit nrxpharma.com.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What are the main products NRx Pharmaceuticals (NRXP) is developing?
How does NRX-101 differ from existing treatments for bipolar depression?
What is the potential impact of NRx Pharmaceuticals' (NRXP) treatments on depression and suicide?
